North America Menopausal Disorder Treatment Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Oct 2020
  • North America
  • 350 Pages
  • No of Tables: 163
  • No of Figures: 48

North America Menopausal Disorder Treatment Market, By Stages (Menopause, Postmenopause, Perimenopause), Type (Hormonal Therapy and Non-Hormonal Therapy), Menopause Symptoms (Vasomotor Symptoms, Atrophic Vaginitis, Osteoporosis, Joint Pain, Weight Gain, Dyspareunia, Depression, Others), Dosage Form (Tablet, Cream, Gels, Rings/Insert, Patch/Film, Injection Shot, Spray, Others), Route of Administration (Oral, Vaginal, Transdermal, Parenteral), End User (Hospital, Clinics, Home Healthcare), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada , Mexico) Industry Trends and Forecast to 2027

North America Menopausal Disorder Treatment MarketMarket Analysis and Insights: North America Menopausal Disorder Treatment Market

North America menopausal disorder treatment market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 7.1% in the forecast period of 2020 to 2027 and is expected to reach USD 8,592.59 million by 2027. Increasing cases of chemotherapy, radiation therapy and hysterectomy and growing cases of hormone related disorders are the major drivers which propelled the demand of the market in the forecast period.

Menopausal disorder treatment comprises features such presence of novel pipeline drugs will impact in Menopausal disorder treatment comprises features such as the presence of novel pipeline drugs which will impact in launching new products by the manufactures into the market which enhance its demand as well as high demand of disease specific treatment leads the demand of accurate menopausal disorder treatment market.

Currently, various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative menopausal disorder treatment which is expected to provide various other opportunities in the menopausal disorder treatment market. However, inadequate knowledge about menopause in some developing countries and availability of alternatives are expected to restraint the menopausal disorder treatment market growth in the forecast period.

The menopausal disorder treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the menopausal disorder treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

North America Menopausal Disorder Treatment MarketNorth America Menopausal Disorder Treatment Market Scope and Market Size

Menopausal disorder treatment market is segmented on the basis of stages, type, menopause symptoms, dosage form, route of administration, end-user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of stages, the menopausal disorder treatment market is segmented into perimenopause, menopause and postmenopause. In 2020, menopause segment is expected to dominate the market as is has been reported to exist for a longer period of time and targets large number of population.
  • On the basis of type, the menopausal disorder treatment market is segmented into hormonal therapy and non-hormonal therapy. In 2020, hormonal therapy segment is expected to dominate the market as it is most commonly used for getting relieve from vaginal dryness and hot flushes among other menopause related disorders.
  • On the basis of menopause symptoms, the menopausal disorder treatment market is segmented into vasomotor symptoms, atrophic vaginitis, dyspareunia, osteoporosis, depression, joint pain, weight gain and others. In 2020, vasomotor symptoms segment is expected to dominate the market as it is the first reported symptom associated with menopause. Moreover, most of the market players are engaged in development of innovative drugs used for menopause disorders.
  • On the basis of dosage form, the menopausal disorder treatment market is segmented into tablet, cream, gels, patch/film, rings, spray, injection shot and others. In 2020, tablet segment is dominating the market due to its high bioavailability and also provides prolonged stability to medicaments used for the treatment of menopause associated disorders.
  • On the basis of route of administration, the menopausal disorder treatment market is segmented into oral, parenteral, transdermal and vaginal. In 2020, oral segment is dominating the menopausal disorder treatment market as it is the easy and safe method of drug administration.
  • On the basis of end user, the menopausal disorder treatment market is segmented into hospital, clinics and home healthcare. In 2020, hospital segment is expected to dominate the market as hospitals are properly equipped with advanced diagnosis tools. Moreover trained professional for parenteral drug administration are also present at hospitals.
  • On the basis of distribution channel, the menopausal disorder treatment market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. In 2020, hospital pharmacy segment is dominating the market because maximum number of patients used to visit hospitals and used to procure medicines from hospital pharmacy.

Menopausal disorder treatment Market Country Level Analysis

North America menopausal disorder treatment market is analyzed and market size information is provided by country, stages, type, menopause symptoms, dosage form, route of administration, end user and distribution channel as referenced above.

The countries covered in North America menopausal disorder treatment market report are the U.S., Canada, and Mexico.

In North America region, menopause segment is expected to grow with the highest growth rate in the forecast period of 2020 to 2027. The U.S. is dominating the North America menopausal disorder treatment market due to rising older female population and research development for identification of effective treatment in the U.S. owing to increased healthcare funding.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Vulnerable Aging Population of Menopause Women and Increasing Cases of Chemotherapy, Radiation Therapy and Hysterectomy are boosting the Market Growth for Menopausal Disorder Treatment.

Menopausal disorder treatment market also provides you with detailed market analysis for every country growth in menopausal disorder treatment industry with menopausal disorder treatment drugs sales, impact of advancement in the menopausal disorder treatment technology and changes in regulatory scenarios with their support for the menopausal disorder treatment market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Menopausal Disorder Treatment Market Share Analysis

Menopausal disorder treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to menopausal disorder treatment market.

The major companies which are dealing in the menopausal disorder treatment are Eli Lilly and Company, Allergan (A Subsidiary of AbbVie, Inc.), TherapeuticsMD, Inc., GlaxoSmithKline plc, Dr. Reddy’s Laboratories Ltd., Ipsen Pharma, Pfizer Inc., Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.), Mylan N.V., Abbott, Besins Healthcare, Mithra Pharmaceuticals, SEBELA PHARMACEUTICALS, Fervent Pharmaceuticals Inc., Sojournix Inc., Duchesnay USA, Novartis AG, Novo Nordisk A/S among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the menopausal disorder treatment market.

For instance,

  • In July 2017, Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.) launched generic Vagifem in the U.S., used for treatment of atrophic vaginitis caused due to menopause. This initiative enhanced the company’s generic product portfolio and allowed it to penetrate its root in menopausal disorder treatment market.
  • In March 2017, Ipsen Pharma received approval from MHRA for Decapeptyl to use for treatment of disorders in pre- menopausal women having early stage breast cancer. This approval helped the company to expand its roots in the menopausal disorder treatment market.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market players are enhancing the company market in the menopausal disorder treatment market which also provides the benefit for organization to improve their offering for menopausal disorder treatment.

Customization Available: North America Menopausal Disorder Treatment Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES

TABLE 1 NORTH AMERICA MENOPAUSAL DISORDER TREATMENT MARKET, PIPELINE ANALYSIS

TABLE 2 MEDICINES SUBJECTED TO PATENT EXPIRY

TABLE 3 NORTH AMERICA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES 2019-2027 (USD MILLION)

TABLE 4 NORTH AMERICA MENOPAUSE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 5 NORTH AMERICA POSTMENOPAUSE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 6 NORTH AMERICA PERIMENOPAUSE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 7 NORTH AMERICA MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2019-2027 (USD MILLION)

TABLE 8 NORTH AMERICA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 9 NORTH AMERICA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 10 NORTH AMERICA HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 11 NORTH AMERICA 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 12 NORTH AMERICA CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 13 NORTH AMERICA ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 14 NORTH AMERICA ESTRADIOL ACETATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 15 NORTH AMERICA HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 16 NORTH AMERICA 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 17 NORTH AMERICA ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 18 NORTH AMERICA CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 19 NORTH AMERICA HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 20 NORTH AMERICA MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 21 NORTH AMERICA NON HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 22 NORTH AMERICA NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 23 NORTH AMERICA NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 24 NORTH AMERICA ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 25 NORTH AMERICA NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 26 NORTH AMERICA HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 27 NORTH AMERICA MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS 2019-2027 (USD MILLION)

TABLE 28 NORTH AMERICA VASOMOTOR SYMPTOMS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 29 NORTH AMERICA ATROPHIC VAGINITIS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 30 NORTH AMERICA OSTEOPOROSIS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 31 NORTH AMERICA JOINT PAIN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 32 NORTH AMERICA WEIGHT GAIN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 33 NORTH AMERICA DYSPAREUNIA IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 34 NORTH AMERICA DEPRRESSION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 35 NORTH AMERICA OTHERS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 36 NORTH AMERICA MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM 2019-2027 (USD MILLION)

TABLE 37 NORTH AMERICA TABLETS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 38 NORTH AMERICA CREAMS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 39 NORTH AMERICA GELS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 40 NORTH AMERICA RINGS/INSERTS/INSERTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 41 NORTH AMERICA PATCH/FILMS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 42 NORTH AMERICA INJECTION SHOT IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 43 NORTH AMERICA SPRAY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 44 NORTH AMERICA OTHERS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 45 NORTH AMERICA MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 46 NORTH AMERICA ORAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 47 NORTH AMERICA VAGINAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 48 NORTH AMERICA TRANSDERMAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 49 NORTH AMERICA PARENTERAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 50 NORTH AMERICA PARENTERAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 51 NORTH AMERICA MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER 2019-2027 (USD MILLION)

TABLE 52 NORTH AMERICA HOSPITAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 53 NORTH AMERICA CLINICS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 54 NORTH AMERICA HOME HEALTHCARE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 55 NORTH AMERICA MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBITION CHANNEL, 2019-2027 (USD MILLION)

TABLE 56 NORTH AMERICA HOSPITAL PHARMACY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 57 NORTH AMERICA RETAIL PHARMACY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 58 NORTH AMERICA ONLINE PHARMACY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 59 NORTH AMERICA MENOPAUSAL DISORDER TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 60 NORTH AMERICA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 61 NORTH AMERICA MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 62 NORTH AMERICA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 63 NORTH AMERICA HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 64 NORTH AMERICA 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 65 NORTH AMERICA CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 66 NORTH AMERICA ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 67 NORTH AMERICA ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 68 NORTH AMERICA ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 69 NORTH AMERICA HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 70 NORTH AMERICA 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 71 NORTH AMERICA ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 72 NORTH AMERICA CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 73 NORTH AMERICA HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 74 NORTH AMERICA MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 75 NORTH AMERICA NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 76 NORTH AMERICA NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 77 NORTH AMERICA ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 78 NORTH AMERICA NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 79 NORTH AMERICA HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 80 NORTH AMERICA MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)

TABLE 81 NORTH AMERICA MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)

TABLE 82 NORTH AMERICA MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 83 NORTH AMERICA PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 84 NORTH AMERICA MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 85 NORTH AMERICA MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 86 U.S. MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 87 U.S. MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 88 U.S. HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 89 U.S. HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 90 U.S. 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 91 U.S. CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 92 U.S. ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 93 U.S. ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 94 U.S. ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 95 U.S. HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 96 U.S. 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 97 U.S. ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 98 U.S. CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 99 U.S. HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 100 U.S. MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 101 U.S. NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 102 U.S. NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 103 U.S. ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 104 U.S. NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 105 U.S. HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 106 U.S. MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)

TABLE 107 U.S. MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)

TABLE 108 U.S. MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 109 U.S. PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 110 U.S. MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 111 U.S. MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 112 CANADA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 113 CANADA MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 114 CANADA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 115 CANADA HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 116 CANADA 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 117 CANADA CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 118 CANADA ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 119 CANADA ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 120 CANADA ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 121 CANADA HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 122 CANADA 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 123 CANADA ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 124 CANADA CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 125 CANADA HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 126 CANADA MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 127 CANADA NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 128 CANADA NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 129 CANADA ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 130 CANADA NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 131 CANADA HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 132 CANADA MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)

TABLE 133 CANADA MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)

TABLE 134 CANADA MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 135 CANADA PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 136 CANADA MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 137 CANADA MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 138 MEXICO MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 139 MEXICO MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 140 MEXICO HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 141 MEXICO HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 142 MEXICO 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 143 MEXICO CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 144 MEXICO ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 145 MEXICO ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 146 MEXICO ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 147 MEXICO HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 148 MEXICO 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 149 MEXICO ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 150 MEXICO CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 151 MEXICO HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 152 MEXICO MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 153 MEXICO NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 154 MEXICO NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 155 MEXICO ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 156 MEXICO NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 157 MEXICO HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 158 MEXICO MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)

TABLE 159 MEXICO MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)

TABLE 160 MEXICO MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 161 MEXICO PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 162 MEXICO MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 163 MEXICO MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions